FTC Merger Scrutiny Will Focus On Category With Five Or Fewer Competitors
Executive Summary
The Federal Trade Commission will take a close look at any merger that leaves five or fewer competitors in a market, Bureau of Competition Deputy Director Ann Malester said
You may also be interested in...
Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers
Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials